BTAI — BioXcel Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2018-03-08.
Performance
Technicals
Others in Healthcare
Measured signals that fired on BTAI
| date | signal | measured base rate |
|---|---|---|
| 2026-03-26 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-15 | Yocca Frank Chief Scientific Officer | Option exercise | 35 | — | — |
| 2026-06-15 | Steinhart Richard I Chief Financial Officer | Option exercise | 35 | — | — |
| 2026-06-15 | Mehta Vimal CEO and President | Option exercise | 219 | — | — |
| 2026-06-15 | Rodriguez Javier See Remarks | Option exercise | 35 | — | — |
| 2026-05-20 | Mehta Vimal CEO and President | Open-market sale 10b5-1 plan | 19.4K | 1.09 | 21.1K |
| 2026-05-20 | Yocca Frank Chief Scientific Officer | Open-market sale 10b5-1 plan | 6.8K | 1.08 | 7.4K |
| 2026-05-20 | Steinhart Richard I Chief Financial Officer | Open-market sale 10b5-1 plan | 6.8K | 1.08 | 7.4K |
| 2026-05-20 | Rodriguez Javier See Remarks | Open-market sale 10b5-1 plan | 6.6K | 1.08 | 7.1K |
| 2026-05-04 | Steinhart Richard I Chief Financial Officer | Option exercise 10b5-1 plan | 17.5K | — | — |
| 2026-05-04 | Rodriguez Javier See Remarks | Option exercise 10b5-1 plan | 17.5K | — | — |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 2.6M | 1.9M |
| ARMISTICE CAPITAL, LLC | 2.6M | 1.9M |
| OAKTREE CAPITAL MANAGEMENT LP | 323.2K | 241.2K |
| GEODE CAPITAL MANAGEMENT, LLC | 308.7K | 230.2K |
| VANGUARD CAPITAL MANAGEMENT LLC | 277.8K | 207.3K |
| JONES FINANCIAL COMPANIES LLLP | 166.1K | 131.8K |
| Man Group plc | 129.3K | 96.5K |
| STATE STREET CORP | 123.4K | 92.1K |
| FMR LLC | 121.0K | 90.3K |
| VANGUARD FIDUCIARY TRUST CO | 113.8K | 84.9K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Bioxcel Therapeutics, Inc. (BTAI) filed form 8-K · 2026-08-11 · SEC EDGAR
Ask the AI about BTAI
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →